{"filings":[{"id":2133405,"accession_number":"0001104659-26-092718","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2026-08-07T20:15:33+00:00","items":["3.01","9.01"],"status":"ready","headline":"Elutia receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Aug 6, 2026 for closing bid below $1.00 for 30 consecutive business days.","Has 180 days, until Feb 2, 2027, to regain compliance by closing at $1.00+ for 10 consecutive days.","May qualify for additional 180-day period if it meets other listing standards and notifies of reverse stock split intent.","Company intends to monitor bid price and assess options; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1748076,"accession_number":"0001104659-26-085061","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2026-07-20T20:06:12+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Elutia signs agreement to sell SimpliDerm business for up to $11M, focuses on NXT-41x launch","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration up to $11M: $8M cash at closing plus up to $3M in technology transfer and commercial milestone payments over 18 months.","Closing expected in H2 2026, subject to customary conditions; buyer is Cellution Biologics Inc.","Proceeds provide non-dilutive capital to advance NXT-41x toward clearance and commercial launch in 2027.","Divestiture sharpens Elutia's focus on the $1.5B plastic and reconstructive surgery market with NXT-41x.","SimpliDerm is a human acellular dermis product for breast reconstruction; sale completes strategic review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1085920,"accession_number":"0001104659-26-074660","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2026-06-16T21:00:09+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Elutia stockholders approve 3M share increase in 2020 Incentive Plan; reelect directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["First Amendment to 2020 Plan increases share authorization by 3M shares, extends termination to June 2036.","Stockholders approved at annual meeting on June 11, 2026; 77% quorum (34M shares present).","Directors David Colpman and Kevin Rakin reelected as Class III directors; 94% and 99% votes cast for.","Advisory say-on-pay approved with ~98% of votes cast in favor; annual frequency adopted.","Ratification of PricewaterhouseCoopers as FY 2026 auditor with ~99% approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442566,"accession_number":"0001104659-26-061150","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2026-05-14T20:06:06+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elutia reports Q1 net loss $7.5M; NXT-41x on track for clearance in H1 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $7.9M vs $1.9M loss in Q1 2025; net loss $7.5M vs $3.9M.","Cash & escrow $36.5M; NXT-41 510(k) clearance expected Q4 2026, NXT-41x clearance H1 2027.","Net sales $3.1M (+6% YoY); SimpliDerm $2.1M, Cardiovascular $1.0M.","Adjusted gross margin 66.5% vs 55.9% YoY; new automated mfg supports >80% gross margin target.","Exploring SimpliDerm divestiture; received inbound inquiries for Cardiovascular product line."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107556,"accession_number":"0001104659-26-026398","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elutia Q4 revenue $3.3M (+16% YoY); NXT-41 510(k) submitted; cash $36.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net sales from continuing ops $3.3M, up 16% YoY; adjusted gross margin 66.8%.","Full year net sales $12.3M; net loss from continuing ops $15.9M; net income $53.4M includes gain on BioEnvelope sale.","Submitted 510(k) for NXT-41 base biologic matrix to FDA; clearance expected H2 2026; full NXT-41x clearance in 1H27.","Closed $88M BioEnvelope sale to Boston Scientific; repaid $26.9M debt; cash $36.4M plus $8M escrow.","Initiated strategic review for SimpliDerm product line to focus on NXT-41x launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107555,"accession_number":"0001104659-26-025311","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Elutia adopts 2026 Inducement Award Plan, authorizing up to 2M shares for new hire grants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board adopted Inducement Plan on March 3, 2026; allows equity grants to new employees as hiring inducement without shareholder approval.","Maximum shares authorized: 2,000,000 shares of Class A common stock.","Awards include stock options (non-ISO), SARs, restricted stock, RSUs, cash-based awards, and dividend equivalents.","Plan administered by Compensation Committee; awards subject to Company's clawback policies.","Grants require press release and Nasdaq notice under Nasdaq Rule 5635(c)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107554,"accession_number":"0001104659-26-023189","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Elutia regains full compliance with Nasdaq minimum bid price and MVLS requirements","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on March 2, 2026, confirming compliance with minimum bid price rule (bid ≥ $1.00 for 10 consecutive days).","Received Nasdaq notice on February 5, 2026, confirming compliance with MVLS requirement (MVLS ≥ $35M for 11 consecutive days).","All Nasdaq continued listing requirements are now met; matters are closed; stock continues trading on Nasdaq Capital Market under symbol ELUT.","CFO Matt Ferguson cites investor confidence in drug-eluting biomatrix technology platform and market opportunity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107553,"accession_number":"0001104659-26-002742","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elutia reports preliminary Q4 2025 revenue $3.3M (+16% YoY); eliminates $26.9M debt","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 net sales ~$3.3M, up 16% YoY, excluding divested BioEnvelope business.","Repaid full $26.9M debt to SWK Holdings, significantly cutting interest expense.","Cash on hand $36.3M; $8M escrow from BioEnvelope divestiture expected in 2026.","Plans FDA filing for NXT-41 base matrix in H1 2026, clearance H2 2026; NXT-41x clearance H1 2027.","CEO cites $88M EluPro divestiture to Boston Scientific as transformational, funding NXT-41x."],"consensus_eps_estimate":null,"consensus_eps_actual":0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":12293000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107552,"accession_number":"0001104659-26-000076","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Elutia receives Nasdaq delisting notice for MVLS below $35M, also still out of compliance with bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice received Dec 23, 2025: MVLS below $35M for 30 consecutive business days.","Company has 180 days (until June 22, 2026) to regain MVLS compliance.","Previously disclosed bid price non-compliance; cure period ends May 6, 2026.","Stock continues trading on Nasdaq Capital Market (ELUT) pending compliance efforts.","Company may seek a reverse stock split if needed to cure bid price deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123916,"accession_number":"0001104659-25-109699","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Elutia receives Nasdaq deficiency notice for bid price below $1.00 per share","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Elutia on Nov 7, 2025 that its common stock closed below $1.00 for 30 consecutive business days.","Company has 180 days (until May 6, 2026) to regain compliance by closing at $1.00+ for 10 consecutive days.","If not cured, Elutia may request an additional 180-day period if it meets market value and other initial listing standards.","Stock continues trading on Nasdaq under 'ELUT' while the company monitors options, including a potential reverse stock split.","No immediate delisting; failure to cure could lead to delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123915,"accession_number":"0001104659-25-107741","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elutia Q3 revenue $3.3M, closes $88M BioEnvelope sale to Boston Scientific, pays off debt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net sales $3.3M (down from $3.7M YoY); loss from operations $5.2M vs $9.2M loss a year ago.","Closed sale of BioEnvelope business to Boston Scientific for $88M; used $27.8M to repay SWK loan facility in full.","Advancing NXT-41x for plastic/reconstructive surgery; FDA clearance of base matrix expected 2H26, drug-eluting version 1H27.","Cash balance $4.7M at Sep 30, 2025; received $80.3M net proceeds on Oct 1, 2025 after closing and escrow.","Settled 7 additional FiberCel cases, leaving only 6 unresolved; Guido J. Neels appointed to Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123914,"accession_number":"0001104659-25-099347","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Elutia appoints medtech veteran Guido Neels to board; Jordan and Zuga resign","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Guido J. Neels elected to board effective Oct 9, 2025; appointed to Audit Committee.","Neels granted option for 171,916 shares at $0.88, vesting over 3 years.","Maybelle Jordan and W. Matthew Zuga resigned Oct 8, 2025; no disagreement cited.","Neels is Operating Partner at EW Healthcare Partners and former COO of Guidant.","Company notes recent EluPro divestiture as context for strategic transformation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123913,"accession_number":"0001104659-25-097561","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["1.01","2.01","7.01","8.01","9.01"],"status":"ready","headline":"Elutia closes $88M sale of BioEnvelope business to Boston Scientific; pivots to NXT-41x","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed sale of CIED/BioEnvelope business to Boston Scientific for $88M cash; $80.3M paid at closing, $8M escrowed for 12 months.","Used $27.8M of proceeds to fully repay and terminate SWK Credit Agreement (principal $24.5M plus fees).","Amended Ligand royalty agreement: paid $1.1M accrued royalties; Ligand consented to sale and released security interest in CIED assets.","Company will focus on NXT-41x drug-eluting biomatrix for breast reconstruction; expects launch first half 2027.","Pro forma cash balance ~$57M; Device Protection Business reported as discontinued operations in future filings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140585,"accession_number":"0001104659-25-088481","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Elutia sells CIED business to Boston Scientific for up to $88M; funds breast reconstruction pipeline","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Asset sale of EluPro/CanGaroo bioenvelope business to Boston Scientific (BSX) for $80M at closing plus $8M escrow.","Proceeds to eliminate outstanding debt, resolve Orthobiologics litigation, and fund NXT-41 advancement without dilution.","Transaction expected to close in Q4 2025, subject to customary closing conditions.","Elutia to focus resources on SimpliDerm franchise and drug-eluting pipeline in the $1.5B US breast reconstruction market.","BofA Securities served as financial advisor to Elutia on the sale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140584,"accession_number":"0001104659-25-080916","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Elutia amends SWK credit facility, capitalizes interest and fees into principal","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Fifth Amendment to $25M senior secured term loan capitalizes accrued interest due Aug 2025, $50k amendment fee (June 30, 2025), and $10k amendment fee.","No new principal borrowed; amendment modifies repayment terms of existing SWK Facility.","Amendment effective Aug 14, 2025; no event of default occurred and continuing.","Borrower represents all conditions precedent satisfied, including payment of $10k amendment fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140583,"accession_number":"0001104659-25-078596","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elutia Q2 BioEnvelope revenue $3.5M (+33% YoY), EluPro sales surge 49% sequentially","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["EluPro drug-eluting envelope revenue up 49% sequentially; now ~2/3 of BioEnvelope sales; average per-customer spend 130% higher vs legacy CanGaroo.","Total Q2 net sales $6.3M (flat YoY); SimpliDerm $2.0M (down from $2.6M); Cardiovascular $0.7M (down from $1.1M).","GAAP gross margin improved to 48.8% (vs 44.5%); adjusted gross margin 62.4% (vs 58.0%); net loss narrowed to $9.6M (vs $28.2M).","Litigation substantially resolved: settled 27 additional FiberCel cases for total 97 of 110; expect reduced litigation expenses.","Pipeline: progressing NXT-41 antibiotic biomatrix for breast reconstruction; FDA clearance targeted 2H26 (base) and 1H27 (drug-eluting); addresses $1.5B market."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":12293000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158291,"accession_number":"0001558370-25-008401","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Elutia annual meeting elects two Class II directors, ratifies PwC as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["29,585,703 shares (80.9% of outstanding) present at May 29, 2025 annual meeting.","Brigid A. Makes elected as Class II director: 19,152,084 FOR, 5,806,525 WITHHELD.","C. Randal Mills, Ph.D. elected as Class II director: 21,801,664 FOR, 3,156,945 WITHHELD.","Ratification of PricewaterhouseCoopers as auditor for FY2025: 29,581,065 FOR, 4,458 AGAINST, 180 abstained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158290,"accession_number":"0001104659-25-046155","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["1.01","2.02","3.02","9.01"],"status":"ready","headline":"Elutia Issues Shares to Ligand, Amends SWK Loan, and Reports 84% Sequential EluPro Growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Issued 1,105,528 shares to Ligand Pharmaceuticals to satisfy $2.2 million in royalty obligations.","Amended SWK credit facility allowing full PIK interest in May 2025 and potential $5.0 million additional term loan.","Reported Q1 2025 net sales of $6.0 million; BioEnvelope sales up 31% year-over-year to $3.1 million driven by 84% sequential EluPro growth.","Entered partnership with Boston Scientific expected to accelerate EluPro adoption starting Q2 2025.","Cash balance of $17.4 million as of March 31, 2025; raised $15.0 million in gross proceeds from direct offering."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":6030000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158289,"accession_number":"0001104659-25-045050","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["1.02","7.01","9.01"],"status":"ready","headline":"Elutia terminates LeMaitre distribution deal, moves to direct cardiovascular sales","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Termination of distribution agreement with LeMaitre Vascular for ProxiCor, VasCure, Tyke products in the U.S.","Appoints Dwayne Montgomery as Head of Cardiovascular; recruits 26 independent sales reps for new direct sales unit.","Expects ~80% gross margins and top-line growth; 2024 cardiovascular product sales were $2.9M (12% of revenue).","No early termination penalties incurred; transition to direct sales has commenced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176670,"accession_number":"0001104659-25-021371","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elutia Q4 2024: BioEnvelope sales +18% to $2.7M; EluPro pilot launch gains traction; net loss $9.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 BioEnvelope sales $2.7M (+18% YoY); overall net sales $5.5M (-7% YoY) due to SimpliDerm and cardiovascular declines.","EluPro accounted for over 30% of BioEnvelope sales in Q4; 67 approved accounts and ~100 actively ordering.","Q4 GAAP gross margin improved to 42.5% (from 36.2%); adjusted gross margin 58.1% (from 50.6%).","Full year 2024 net loss from continuing ops $54.1M vs $41.2M; adjusted EBITDA loss narrowed to $12.9M from $14.4M.","Year-end cash $13.2M; raised ~$15M gross proceeds in February 2025 registered direct offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176669,"accession_number":"0001104659-25-009187","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Elutia raises $15M in registered direct offering; sells 5.52M shares at $2.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $15.0M from sale of 5,520,000 shares at $2.50 and 480,000 prefunded warrants at $2.499.","Prefunded warrants have $0.001 exercise price, exercisable immediately, and expire when fully exercised.","Net proceeds to be used for working capital and general corporate purposes.","Directors and officers subject to 90-day lock-up; company also restricted from issuing equity for 90 days post-close."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176668,"accession_number":"0001104659-25-008297","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Elutia prelim FY2024 net sales $24.4M, down 1% YoY; cardiovascular sales plunge 42%","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Preliminary 2024 net sales $24.4M vs $24.7M in 2023, a 1% decline.","Women's health sales grew 12% to $11.6M; device protection up 5% to $9.9M.","Cardiovascular sales fell 42% to $2.9M, dragging overall results.","Results are preliminary; final numbers subject to adjustment upon completion of year-end close.","No further financial details provided; full 10-K to follow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193507,"accession_number":"0001104659-24-118906","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elutia Q3 net sales $5.9M (-3.3%); EluPro adoption accelerates with 100+ VAC submissions","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Overall Q3 net sales $5.9M, down 3.3% YoY; BioEnvelope sales down 12% to $2.3M as customers await EluPro.","SimpliDerm sales up 19% to $3.1M; adjusted gross margin improved to 61% from 60%.","Net income from cont. ops $1.3M driven by $12.7M non-cash warrant revaluation gain; adjusted EBITDA loss $2.9M.","EluPro: first patient implant, over 100 VAC submissions, 36 accounts ordering; full commercial launch set for Jan 2025.","Cash balance $25.7M as of Sep 30, 2024, includes $13.8M from warrant exercises in early Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":18907000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193506,"accession_number":"0001104659-24-105839","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Elutia amends credit agreement, deferring principal repayments by one year to Nov 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal repayment commencement deferred from Nov 15, 2024 to Nov 15, 2025.","Interest paid-in-kind election extended to Nov 15, 2025.","Exit fee increased by $50,000 to 6.50% plus $112,500.","SWK Facility remains a $25M senior secured term loan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209814,"accession_number":"0001104659-24-086740","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elutia Q2 net loss widens to $28.2M on warrant revaluation; EluPro launch underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $28.2M vs $10.6M YoY; includes $18.3M non-cash warrant revaluation charge.","Total net sales flat at $6.3M; CanGaroo +19% to $2.6M, SimpliDerm +7% to $2.6M.","FDA clearance for EluPro received; manufacturing commenced; commercial team expanding.","Cash $18.2M at quarter end; $13.8M additional from post-quarter warrant exercises.","Adjusted EBITDA loss improved to $2.9M from $3.4M in prior-year quarter."],"consensus_eps_estimate":-0.1734,"consensus_eps_actual":-1.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":12985000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228012,"accession_number":"0001104659-24-072818","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Elutia raises $13.26M in registered direct offering of 3.175M shares and prefunded warrants at $3.40/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$13.26M from sale of 3,175,000 shares and 725,000 prefunded warrants.","Offering price $3.40 per share; prefunded warrants $3.399 each, exercisable at $0.001.","Net proceeds to be used for working capital and general corporate purposes.","Lake Street Capital Markets acted as placement agent; 7.0% cash fee on gross proceeds.","Directors and officers subject to 90-day lock-up on company securities post-closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228011,"accession_number":"0001104659-24-072044","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Elutia receives FDA clearance for antibiotic-eluting bioenvelope EluPro for cardiac and neuromodulation devices","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared EluPro, first antibiotic-eluting bioenvelope, for pacemakers, defibrillators, neurostimulators, and neuromodulators.","Targets $600M US implantable electronic device protection market; no other biologic competitor currently.","Delivers rifampin and minocycline embedded in extracellular matrix to reduce infection, migration, and erosion complications.","Additional indications expand addressable market to neurostimulation/modulation, estimated at $8B worldwide.","Elutia plans national CIED launch in H2 2024; adjacent neuro markets prioritized for expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228010,"accession_number":"0001558370-24-009020","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Elutia stockholders elect Maybelle Jordan and W. Matthew Zuga as Class I Directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Turnout 12,975,682 shares (64.8% of outstanding Class A common stock) at June 6, 2024 annual meeting.","Maybelle Jordan received 10,789,009 votes FOR (160,550 withheld) to serve as Class I director until 2027.","W. Matthew Zuga received 10,670,337 votes FOR (279,222 withheld) to serve as Class I director until 2027.","Ratification of PwC as independent auditor for FY 2024: 12,966,730 FOR, 251 AGAINST, 8,701 ABSTAINED."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228009,"accession_number":"0001104659-24-059460","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elutia Q1 net sales $6.7M; SimpliDerm up 55%; CanGarooRM FDA decision expected by June 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["SimpliDerm net sales $3.6M (+55% YoY) driven by accelerated adoption in $1.6B breast reconstruction market.","CanGarooRM antibiotic-envelope 510(k) submission; positive FDA interactions; clearance anticipated Q2 2024.","Net loss $18.0M includes $9.6M non-cash warrant revaluation; adjusted EBITDA loss improved to $3.6M.","Cash balance $12.6M; preparing for CanGarooRM commercial launch in H2 2024.","Overall net sales $6.7M (+5% YoY); cardiovascular sales declined 56% due to LeMaitre distribution transition."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":6694000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228008,"accession_number":"0001558370-24-004550","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Elutia amends credit agreement, reducing minimum revenue covenant to $20M from $41M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Second Amendment with SWK Funding LLC lowers minimum Aggregate Revenue to $20M for trailing twelve months from Q1 2024 onward.","Previous covenant was $41M for Q2 2023 and each subsequent quarter; now reduced to $20M.","Amendment executed March 27, 2024; filed as Exhibit 10.1 on April 1, 2024.","No other material terms changed; CFO Matt Ferguson signed on behalf of Elutia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246772,"accession_number":"0001104659-24-031918","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elutia reports FY23 net loss $37.7M, cash $19.3M; CanGarooRM 510(k) decision expected H1 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year net sales $24.7M vs $23.8M; SimpliDerm up 38%, CanGaroo up 3.4%.","GAAP gross margin 45%; adjusted gross margin 58%; net loss $37.7M vs $32.9M.","Adjusted EBITDA loss improved to $14.6M from $22.9M.","Cash $19.3M as of Dec 31, 2023; proceeds $14.6M from orthobiologics divestiture.","FDA 510(k) decision for CanGarooRM expected in first half 2024; no additional data requested."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246771,"accession_number":"0001104659-24-010063","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Elutia reprices stock options and grants new equity to CEO, CFO, CSO, and other employees","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO C. Randal Mills' existing options and RSUs vesting thresholds lowered to $6, $10, $14, $18 per share.","CEO granted 650,000 options and 650,000 RSUs; CFO and CSO each granted 200,000 options and 200,000 RSUs.","Non-executive employee options repriced from >$7 to $3.61 per share, covering 144,427 shares.","New equity grants to other employees include 565,561 options and 1,167,500 RSUs.","Vesting of some awards contingent on FDA clearance of CanGarooRM antibiotic-eluting envelope."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246770,"accession_number":"0001558370-24-000247","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2024-01-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Elutia amends Ligand royalty deal; min annual payment rises to $4.4M, $5M milestone waived","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Minimum Annual Royalty increased from $2.75M to $4.4M for 2024 and each year thereafter through May 2027.","Quarterly minimum payment raised from ~$0.7M to $1.1M; $3.0M lump-sum paid for 2023 Q1-Q3 (half due Jan 20, 2024, half by Apr 10, 2024).","Ligand waived a $5.0M milestone payment that was due in Q2 2023; royalty rate remains 5% of sales on CanGaroo, ProxiCor, Tyke, VasCure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246769,"accession_number":"0001558370-24-000187","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2024-01-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Elutia regains compliance with Nasdaq board independence and market value standards; delisting appeal canceled","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Jan 9, 2024 confirming compliance with board independence rule (majority independent directors).","Previously regained compliance with market value standard (Rule 5550(b)(2)); all listing requirements now satisfied.","Scheduled hearing with Nasdaq Hearings Panel to appeal prior delisting determinations has been canceled.","Class A common stock continues to trade on Nasdaq Capital Market under symbol ELUT."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264220,"accession_number":"0001558370-23-020013","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2023-12-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Elutia regains Nasdaq MVLS compliance; board independence hearing remains","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Dec 22, 2023 that MVLS requirement met with market value above $35M for 10+ consecutive trading days.","Previous delisting appeal hearing set for Jan 25, 2024 no longer needed for MVLS issue.","Still non-compliant with Nasdaq Board Independence Rule; expects resolution in first week of January 2024.","Non-compliance with board rule does not immediately affect listing or trading of ELUT common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264219,"accession_number":"0001104659-23-124676","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2023-12-08T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Elutia gets Nasdaq delisting notice over board independence issue; hearing Feb 15, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Dec 6, 2023, Nasdaq notified Elutia it is not compliant with Board Independence Rule (majority independent). Currently 3/6 directors independent.","Non-compliance stems from losing 'controlled company' status Dec 2022; transition period expired Dec 5, 2023.","Elutia expects to cure by first week Jan 2024 via director changes (resignation or new appointments).","Delisting matter will be considered alongside existing Market Value Standard non-compliance at Feb 15, 2024 hearing.","Trading of ELUT stock on Nasdaq continues without immediate effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264218,"accession_number":"0001558370-23-019243","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2023-11-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Elutia recasts 2022 financials to reflect sale of Orthobiologics business as discontinued operations","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed sale of Orthobiologics business to Berkeley Biologics LLC on November 8, 2023 for an undisclosed amount.","Asset Purchase Agreement with Berkeley dated September 17, 2023 triggered discontinued operations classification.","Historical results of Orthobiologics business reclassified as discontinued operations in recast 2022 Form 10-K.","Company now operates three segments: Device Protection, Women's Health, and Cardiovascular after sale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264217,"accession_number":"0001104659-23-118801","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2023-11-15T23:59:59+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"Elutia closes Orthobiologics sale to Berkeley Biologics for ~$14.6M cash plus up to $20M earn-out","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sale completed Nov 8, 2023; initial cash payment of ~$14.6M after customary adjustments.","Eligible for earn-out payments of 10% of annual revenue (capped at $20M) over 5 years.","Repaid $2.0M of SWK credit facility at closing; additional $2.0M due by Feb 15, 2024.","Entered 2-year manufacturing agreement with Berkeley for SimpliDerm product.","Pro forma continuing ops: net loss $26.0M for 9mo 2023 (discontinued ops removed)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264216,"accession_number":"0001104659-23-117257","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elutia Q3 net sales $6.1M (+5% YoY); proprietary products up 26%; narrows net loss; to file 510(k) for CanGarooRM in Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $8.5M ($0.50/sh), improving from $11.0M ($0.81/sh) YoY.","Proprietary product sales (SimpliDerm +44%, CanGaroo +11% YoY) drove 26% overall proprietary growth; total net sales $6.1M.","Completed Orthobiologics divestiture for initial $15M, plus private placement netting $10.5M; cash balance $14.5M at Sept 30.","Anticipates FDA 510(k) filing for CanGarooRM by year-end 2023, targeting $600M drug-eluting CIED envelope market.","Operating expenses down 14% YoY to $10.2M; gross margin declined to 46.4% from 50.2% due to distributor pricing shift."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":18870000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264215,"accession_number":"0001104659-23-116047","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Elutia closes Orthobiologics divestiture for up to $35M in cash proceeds","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront payment of $15M due Nov 17, 2023, plus up to $20M earnout over 5 years.","Combined with Sept 2023 private placement, total potential cash exceeds $60M.","Company refocuses on drug-eluting biomatrix platform, including CanGaroo RM.","Transaction closed Nov 8; buyer is Berkeley Biologics (GNI Group subsidiary).","Mizuho Securities acted as financial advisor; Kilpatrick Townsend as legal advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264214,"accession_number":"0001104659-23-115224","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Elutia receives Nasdaq delisting notice for failure to meet MVLS standard; plans to appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received delisting determination from Nasdaq on Nov 1, 2023 for failing to maintain MVLS >= $35M for 10 consecutive days by Oct 31 compliance date.","Trading suspension scheduled for Nov 10, 2023 unless appeal is requested.","Company intends to request hearing with Nasdaq Hearings Panel to appeal; hearing stay pending outcome.","If delisted, trading could become more difficult, stock price may decline materially, and capital raising ability may be impaired.","Stock continues to trade under ELUT on Nasdaq Capital Market pending hearing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281462,"accession_number":"0001104659-23-102812","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2023-09-21T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Elutia raises $10.5M in PIPE with up to $26.2M from warrants; plus divestiture >$60M total cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial gross proceeds ~$10.5M from sale of 7.36M shares/pre-funded warrants and 11.03M common warrants.","Full exercise of warrants would add $15.8M, bringing total PIPE proceeds to $26.2M.","Combined with Orthobiologics divestiture (announced Sep 18), total cash added >$60M.","Warrants exercisable at $1.4275 until 30 trading days post-FDA clearance of CanGarooRM or 5 years.","Investors include existing HighCape Capital, new Nantahala Capital, and a life-sciences fund."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281461,"accession_number":"0001104659-23-101780","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2023-09-19T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Elutia sells Orthobiologics unit to Berkeley Biologics for up to $35M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash $15M at close; earn-out payments up to $20M over 5 years (10% of annual revenue from Earn-Out Products, capped at $20M).","Transaction expected to close in Q4 2023; subject to customary conditions including regulatory approvals and material consents.","Elutia to focus on drug-eluting biomatrix platform; lead product CanGaroo RM targets FDA clearance and launch in H1 2024.","Berkeley Biologics is a wholly-owned subsidiary of GNI Group Ltd. (Tokyo: 2160.T).","Elutia will enter a Manufacturing Agreement for SimpliDerm product for two years following closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281460,"accession_number":"0001104659-23-098809","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2023-09-07T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Aziyo Biologics rebrands as Elutia; shifts to drug-eluting biomatrices; ticker now ELUT","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change to Elutia Inc. effective Sept 6, 2023; ticker switches from AZYO to ELUT on Nasdaq on Sept 7.","Rebranding reflects strategic focus on drug-eluting biomatrix (DEB) technology to improve surgical outcomes.","First DEB product CanGaroo RM for pacemaker/defibrillator market expected to launch next year; market valued at $600M.","Developing SimpliDerm RM for breast reconstruction ($500M market) to address post-op infection rates exceeding 10%.","CEO Randy Mills highlights commitment to DEB technology; no immediate financial impact or guidance provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281459,"accession_number":"0001104659-23-091383","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aziyo Q2 net sales $10.3M, net loss $10.6M; bone matrix recall drives $3M revenue reversal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $10.3M, down from $12.6M YoY; recall reversal of $3.0M of Q2 revenue.","Gross margin 9.5% vs 38.8% prior year; recall cut gross profit by $5.0M and margin by 35%.","Net loss $10.6M ($0.65 per share) vs $9.4M ($0.69 per share) YoY; cash $9.3M at June 30.","Negotiating multiple LOIs to divest Orthopedic business; SimpliDerm up 32% YoY.","CanGaroo RM 510(k) resubmission on track; working with FDA/CDC on viable bone matrix recall."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":23346000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281458,"accession_number":"0001104659-23-080808","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2023-07-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aziyo voluntarily recalls viable bone matrix products after two MTB infections","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Voluntary recall of all viable bone matrix products used in orthopedic/spinal procedures.","Two patients treated with product from a single donor lot developed post-surgical Mycobacterium tuberculosis infections.","Shipments of all viable bone matrix products from all donor lots suspended out of caution.","Company coordinating with FDA and CDC to investigate source and notify physicians for post-exposure prophylaxis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300280,"accession_number":"0001104659-23-069939","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Aziyo shareholders elect two directors, ratify auditor, approve incentive plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected David Colpman and Kevin Rakin as Class III directors until 2026 annual meeting.","Ratified PricewaterhouseCoopers as independent auditor for fiscal year 2023.","Approved Amended and Restated 2020 Incentive Award Plan.","All proposals passed; over 85% outstanding shares represented at meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300279,"accession_number":"0001104659-23-058445","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","3.01","9.01"],"status":"ready","headline":"Aziyo reports record Q1 sales $13.1M; Nasdaq warns MVLS below $35M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales rose 14% YoY to record $13.1M; gross margin improved to 49% from 37%.","Net loss $8.0M ($0.49 per share) vs $8.1M ($0.60) in Q1 2022.","Partnerships with LeMaitre Vascular and Sientra to expand distribution of cardiovascular and SimpliDerm products.","Nasdaq notified company its MVLS was below $35M; 180-day compliance period ends Oct 31, 2023.","Cash balance $11.8M; FDA meeting confirmed path to resubmit CanGaroo RM 510(k)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":13050000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300278,"accession_number":"0001558370-23-006381","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2023-04-21T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Aziyo Biologics grants LeMaitre exclusive US distribution rights for cardiovascular products","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three-year exclusive US distribution deal for ProxiCor PC, ProxiCor CTR, Tyke, and VasCure.","LeMaitre has an exclusive option to acquire the product line after year one; price based on multiple of trailing 12-month sales.","Initial purchase and minimum purchase volumes start Oct 1, 2023; prices subject to annual adjustment.","Aziyo CEO cites focus on CanGaroo Envelope for implantable electronic devices after this partnership.","LeMaitre President says the deal adds next-gen extracellular matrix patches to its US product offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320316,"accession_number":"0001104659-23-035590","cik":1708527,"company_name":"ELUTIA INC.","ticker":"ELUT","form_type":"8-K","filed_at":"2023-03-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Record FY2022 revenue $49.2M; FDA delays CanGaroo RM; Q4 net loss narrows","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2022 net sales $49.2M (+4% YoY); ex-discontinued FiberCel, current product sales up 16%.","Q4 net sales $12.7M (+17% YoY); CanGaroo and SimpliDerm combined grew 30%.","FDA delayed clearance of CanGaroo RM Antibacterial Envelope; company cutting costs to extend cash runway.","Q4 gross margin improved to 39% (non-GAAP 46%); net loss per share $0.38 vs $0.82 YoY.","Entered U.S. distribution agreement with Sientra for SimpliDerm; cash $17.0M at Dec 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":48629056.01769912,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-03-22T23:59:59+00:00|320316"}